Published in PLoS One on June 24, 2010
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
A guide to choosing fluorescent proteins. Nat Methods (2005) 18.55
Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol (2002) 6.37
Anthrax toxin. Annu Rev Cell Dev Biol (2003) 5.92
Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem (2007) 5.38
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol (2003) 3.97
The proprotein convertases. Curr Opin Chem Biol (1998) 3.79
Fluorescent protein FRET pairs for ratiometric imaging of dual biosensors. Nat Methods (2008) 2.56
Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell (1986) 2.38
The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol (2008) 2.38
Proteases: multifunctional enzymes in life and disease. J Biol Chem (2008) 2.30
alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A (1998) 2.28
Capillary morphogenesis protein-2 is the major receptor mediating lethality of anthrax toxin in vivo. Proc Natl Acad Sci U S A (2009) 2.22
Fluorescence proteins, live-cell imaging, and mechanobiology: seeing is believing. Annu Rev Biomed Eng (2008) 2.16
Determination of hierarchical relationship of Src and Rac at subcellular locations with FRET biosensors. Proc Natl Acad Sci U S A (2008) 1.97
Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci (2007) 1.63
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect Immun (1999) 1.58
Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog (2001) 1.56
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer. Cancer Res (2010) 1.50
Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J (2006) 1.49
Activation of human furin precursor processing endoprotease occurs by an intramolecular autoproteolytic cleavage. J Biol Chem (1992) 1.42
A second mutant allele of furin in the processing-incompetent cell line, LoVo. Evidence for involvement of the homo B domain in autocatalytic activation. J Biol Chem (1995) 1.41
Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem (2008) 1.40
Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol (2003) 1.39
Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem (2001) 1.32
Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem (2005) 1.30
Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest (2008) 1.27
Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci (2005) 1.27
Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci U S A (2001) 1.26
Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol (2007) 1.24
Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem (2009) 1.20
Visualization of polarized membrane type 1 matrix metalloproteinase activity in live cells by fluorescence resonance energy transfer imaging. J Biol Chem (2008) 1.18
The family of pro-hormone and pro-protein convertases. Biochem Soc Trans (1993) 1.12
Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol (2003) 1.12
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Quantum dot FRET biosensors that respond to pH, to proteolytic or nucleolytic cleavage, to DNA synthesis, or to a multiplexing combination. J Am Chem Soc (2008) 1.03
Role of cytoplasmic domain serines in intracellular trafficking of furin. Mol Biol Cell (2004) 1.03
A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine. Br J Pharmacol (2007) 1.03
Fluorescence (Förster) resonance energy transfer imaging of oncogene activity in living cells. Cancer Sci (2006) 1.03
Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. J Virol (2007) 1.02
Mammalian paired basic amino acid convertases of prohormones and proproteins. Ann N Y Acad Sci (1993) 0.97
Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS One (2009) 0.97
Development and application of a GFP-FRET intracellular caspase assay for drug screening. J Biomol Screen (2000) 0.94
A membrane-bound FRET-based caspase sensor for detection of apoptosis using fluorescence lifetime and total internal reflection microscopy. Cytometry A (2009) 0.94
A study of human furin specificity using synthetic peptides derived from natural substrates, and effects of potassium ions. Arch Biochem Biophys (2009) 0.93
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin. Int J Biochem Cell Biol (2005) 0.93
Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Arch Biochem Biophys (2005) 0.87
Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor. Infect Immun (2002) 0.86
Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol (2010) 0.84
Unexpected similarity between the cytosolic West Nile virus NS3 and the secretory furin-like serine proteinases. Biochem J (2006) 0.82
In vivo dynamics of enterovirus protease revealed by fluorescence resonance emission transfer (FRET) based on a novel FRET pair. Biochem Biophys Res Commun (2006) 0.81
FRET evidence that an isoform of caspase-7 binds but does not cleave its substrate. Conf Proc IEEE Eng Med Biol Soc (2006) 0.77
Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol (2003) 7.89
Rapid signal transduction in living cells is a unique feature of mechanotransduction. Proc Natl Acad Sci U S A (2008) 3.04
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
The role of the dynamics of focal adhesion kinase in the mechanotaxis of endothelial cells. Proc Natl Acad Sci U S A (2002) 2.01
Determination of hierarchical relationship of Src and Rac at subcellular locations with FRET biosensors. Proc Natl Acad Sci U S A (2008) 1.97
Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci (2007) 1.63
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer. Cancer Res (2010) 1.50
Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J (2006) 1.49
HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol (2007) 1.40
Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem (2008) 1.40
Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem (2007) 1.40
Effects of flow patterns on the localization and expression of VE-cadherin at vascular endothelial cell junctions: in vivo and in vitro investigations. J Vasc Res (2005) 1.37
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem (2001) 1.35
A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases. J Biol Chem (2002) 1.33
Efficient synthetic inhibitors of anthrax lethal factor. Proc Natl Acad Sci U S A (2005) 1.32
Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem (2005) 1.30
Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res (2002) 1.27
The spatiotemporal pattern of Src activation at lipid rafts revealed by diffusion-corrected FRET imaging. PLoS Comput Biol (2008) 1.27
Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem (2006) 1.27
Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem (2009) 1.24
An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem (2001) 1.24
Long-range mechanical force enables self-assembly of epithelial tubular patterns. Proc Natl Acad Sci U S A (2012) 1.24
Substrate rigidity regulates Ca2+ oscillation via RhoA pathway in stem cells. J Cell Physiol (2009) 1.21
Integrins in mechanotransduction. Curr Opin Cell Biol (2013) 1.21
The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem (2003) 1.20
Rapid activation of Rac GTPase in living cells by force is independent of Src. PLoS One (2009) 1.20
Visualization of polarized membrane type 1 matrix metalloproteinase activity in live cells by fluorescence resonance energy transfer imaging. J Biol Chem (2008) 1.18
The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS One (2012) 1.18
Visualization of Src activity at different compartments of the plasma membrane by FRET imaging. Chem Biol (2009) 1.18
The Wnt/planar cell polarity protein-tyrosine kinase-7 (PTK7) is a highly efficient proteolytic target of membrane type-1 matrix metalloproteinase: implications in cancer and embryogenesis. J Biol Chem (2010) 1.17
Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res (2008) 1.14
Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res (2003) 1.13
Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One (2009) 1.11
The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP). J Cell Sci (2005) 1.10
Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation (2009) 1.09
Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol (2003) 1.08
Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J (2002) 1.08
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res (2012) 1.08
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem (2007) 1.08
Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem (2007) 1.08
Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Biochem J (2007) 1.07
Detection of focal adhesion kinase activation at membrane microdomains by fluorescence resonance energy transfer. Nat Commun (2011) 1.06
The two-component NS2B-NS3 proteinase represses DNA unwinding activity of the West Nile virus NS3 helicase. J Biol Chem (2008) 1.04
Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells. Exp Cell Res (2004) 1.04
Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. Int J Cancer (2010) 1.04
Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest (2002) 1.03
Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res (2006) 1.03
The cytoplasmic tail peptide sequence of membrane type-1 matrix metalloproteinase (MT1-MMP) directly binds to gC1qR, a compartment-specific chaperone-like regulatory protein. FEBS Lett (2002) 1.02
Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. J Virol (2007) 1.02
Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem (2010) 1.02
Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol (2004) 1.02
Proteolysis of the membrane type-1 matrix metalloproteinase prodomain: implications for a two-step proteolytic processing and activation. J Biol Chem (2007) 1.01
VE-cadherin trans-interactions modulate Rac activation and enhancement of lung endothelial barrier by iloprost. J Cell Physiol (2012) 1.00
Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. Cancer Res (2013) 0.99
N-cadherin regulates spatially polarized signals through distinct p120ctn and β-catenin-dependent signalling pathways. Nat Commun (2013) 0.98
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res (2006) 0.97
Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS One (2009) 0.97
O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP). J Biol Chem (2006) 0.97
Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res (2004) 0.96
Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis. J Biol Chem (2009) 0.95
Expression and purification of a two-component flaviviral proteinase resistant to autocleavage at the NS2B-NS3 junction region. Protein Expr Purif (2006) 0.95
Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene (2005) 0.94
Distinct biophysical mechanisms of focal adhesion kinase mechanoactivation by different extracellular matrix proteins. Proc Natl Acad Sci U S A (2013) 0.94
Immunodominant fragments of myelin basic protein initiate T cell-dependent pain. J Neuroinflammation (2012) 0.94